Insulet Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ashley A. McEvoy
- Full Time Employees
- 5,400
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 100 Nagog Park Acton MA United States 01720
- IPO Date
- May 15, 2007
- CIK
- 0001145197
- Website
- insulet.com
- Similar Companies
- Business
- Insulet Corporation (NASDAQ: PODD) is a medical device company that designs, develops, manufactures and commercializes innovative tubeless insulin delivery systems and related products primarily for people with diabetes; its flagship Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors for automated insulin dosing via a smartphone app or dedicated controller, the Omnipod DASH Insulin Management System featuring Bluetooth-enabled touchscreen control and waterproof tubeless Pods delivering continuous insulin for up to 72 hours without needles, the Omnipod GO pre-filled disposable Pod system for type 2 diabetes patients requiring basal insulin, and the core Omnipod Insulin Management System offering wearable needle-free delivery; the company also pursues applications of its Pod technology for non-insulin subcutaneous drug delivery in other therapeutic areas through its Drug Delivery segment. Headquartered in Acton, Massachusetts, and founded in 2000, Insulet operates highly automated manufacturing facilities with key geographic presence in the US, Europe, Asia Pacific, the Middle East, Australia and select emerging markets including China and Malaysia, serving approximately 500,000 global customers across 25 countries. In recent developments, the company completed acquisitions of automated insulin delivery assets from Bigfoot Biomedical and Automated Glucose Control LLC for $25 million each to bolster its Omnipod 5 technology, announced a proposed $450 million senior unsecured notes offering due 2033 and amendments to its credit agreement extending revolving credit facility maturity to 2030 with commitments increased to $500 million to redeem its 0.375% Convertible Senior Notes due 2026 including the remaining $380 million principal, integrated Omnipod 5 with Dexcom G7 in multiple European markets alongside new CGM reimbursements in Norway, extended its supply agreement with NXP USA effective 2025 for critical manufacturing components, redeemed outstanding convertible notes, and raised its fiscal 2025 revenue growth guidance to 28-29% at constant currency while outlining a long-term strategy targeting 20% revenue CAGR through 2028 driven by global expansion, operational efficiencies and innovation.
Company News
What Insulet (PODD) Said on Its Q3 Earnings Call
Insulet Corporation (PODD) Q3 2026 Earnings Call Transcript
Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Insulet (PODD) Q3 Earnings and Revenues Surpass Estimates
Insulet Reports Third Quarter 2026 Results
Insulet to Participate in the 2026 Jefferies Global Healthcare Conference in London
Insulet Corporation $PODD Stock: International Assets Investment Management LLC Boosts Stake
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
Insulet Corporation $PODD Shares Sold by Curated Wealth Partners LLC
Here's Why Insulet (PODD) is a Strong Growth Stock
Insulet Announces Omnipod Discover Now Available in U.S.
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
California State Teachers Retirement System Has $2.22 Billion Stock Position in Insulet Corporation $PODD
Insulet Corporation $PODD Stock Position Raised by Amundi